SCHEMBL2371797

SCHEMBL2371797

COc1ccc(Oc2ccc(Br)c(F)c2C(=O)O)c(F)c1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.44
POLB P06746 1/20 0.44
LMNA P02545 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
RAB9A P51151 1/20 0.42
TSHR P16473 2/20 0.39
MEN1 O00255 1/20 0.39
GFER P55789 1/20 0.39
KMT2A Q03164 1/20 0.39
ALDH1A1 P00352 2/20 0.38
CPS1 P31327 1/20 0.38
SCN8A Q9UQD0 2/20 0.38
SCN10A Q9Y5Y9 2/20 0.38
FFAR1 O14842 1/20 0.38
PPARD Q03181 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2371199 0.80 KDM4E (0.51) KDM4EPOLBLMNAMAPK1HTT
SCHEMBL29570123 0.80 CA12 (0.53) KDM4ELMNAMAPK1HTTRAB9A
SCHEMBL2369905 0.78 KDM4E (0.56) KDM4EPOLBLMNAMAPK1HTT
SCHEMBL2372069 0.78 LMNA (0.48) KDM4EPOLBLMNAMAPK1HTT
SCHEMBL2372284 0.76 POLB (0.68) KDM4EPOLBLMNAMAPK1HTT
SCHEMBL31697288 0.73 SCN10A (0.46) KDM4ELMNAMAPK1HTTRAB9A
SCHEMBL22208769 0.73 SCN10A (0.46) KDM4ELMNAMAPK1HTTRAB9A
SCHEMBL1495338 0.70 CA12 (0.48) KDM4ELMNAMAPK1HTTRAB9A
SCHEMBL15832059 0.70 TUBB1 (0.47) KDM4EPOLBMAPK1RAB9AMEN1
SCHEMBL8516100 0.69 HSD17B10 (0.62) KDM4EPOLBLMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883782-B2 Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2014-11-11 US disclosed
EP-2547685-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS Amgen Inc. (US) 2013-01-23 EP disclosed
US-20110251190-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2011-10-13 US disclosed
WO-2011115938-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS AMGEN INC. (US) 2011-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251190-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE BACE1, BACE2, APP KDM4E 2994/4885POLB 3640/4885LMNA 1131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.